



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/088,801

09/18/2002

Finoula Mary Brennan

20020113.ORI

4930

7590

11/15/2006

C G Merereau

Nikolai & Mersereau

820 International Centre

900 Second Avenue South

Minneapolis, MN 55402-3813

EXAMINER

SKELDING, ZACHARY S

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 11/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.

10/088,801

Examiner

Zachary Skelding

Applicant(s)

BRENNAN ET AL.

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on 30 August 2006 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- ☐ 1. Amendments to the specification:
- ☐ A. Amended paragraph(s) do not include markings.
 - ☐ B. New paragraph(s) should not be underlined.
 - ☐ C. Other _____.
- ☒ 2. Abstract:
- ☐ A. Not presented on a separate sheet. 37 CFR 1.72.
 - ☒ B. Other See Continuation Sheet.
- ☐ 3. Amendments to the drawings:
- ☐ A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
 - ☐ B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.
 - ☐ C. Other _____.
- ☐ 4. Amendments to the claims:
- ☐ A. A complete listing of all of the claims is not present.
 - ☐ B. The listing of claims does not include the text of all pending claims (including withdrawn claims)
 - ☐ C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
 - ☐ D. The claims of this amendment paper have not been presented in ascending numerical order.
 - ☐ E. Other: _____.
- ☐ 5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4):

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714.

TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

- Applicant is given **no new time period** if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the **entire corrected amendment** must be resubmitted.
- Applicant is given **one month**, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action. If any of above boxes 1. to 4. are checked, the correction required is only the **corrected section** of the non-compliant amendment in compliance with 37 CFR 1.121.

Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.

Failure to timely respond to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.


Zachary Skelding

Legal Instruments Examiner (LIE), if applicable

571-272-0551

Telephone No.

Continuation of 2(b) Other: applicant has amended the abstract but not included markings to indicate changes made..



PATENT APPLICATION

Our Docket No. 20020113.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Fionula M. Brennan et al : August 24, 2006
S.N. : 10/088,801 : Art Group 1644
Filed : September 18, 2002 : Examiner Sanjoo Jalla
For : THERAPEUTIC METHODS AND COMPOUNDS

AMENDMENT UNDER 37 CFR 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is submitted in response to a non-final Official Action dated February 27, 2006 which carried a shortened-statutory period for reply set to expire three months from that date or on May 27, 2006.

A Petition for a three-month extension of time, together with the requisite fee, is submitted with this response to extend that period until August 27, 2006.

It is requested that the following amendments be entered:

AMENDMENTS TO THE SPECIFICATION

Please cancel the present Abstract and substitute the following for it:

A method of identifying a compound with efficacy in the treatment of chronic inflammatory disease by testing the compound for an ability to selectively inhibit the ability of T_{ck} cells to induce pro-inflammatory cytokine release from a monocyte is disclosed. The method includes pre-incubating T_{ck} cells with a compound to be tested, optionally resuspending the T_{ck} cells in the absence of the test compound, co-culturing the T_{ck} cells with monocytes, and assaying for the production of pro-inflammatory cytokines by the monocytes. The T_{ck} cells are produced by incubating a population of T cells with one or more cytokines or the T_{ck} cells are isolated from synovial tissue. The T_{ck} cells have not been contacted with an anti-CD3 antibody. The ability to selectively inhibit cytokine release indicates that the compound has efficacy in the treatment of chronic inflammatory disease.